Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $46
Benzinga Newsdesk 5 days ago
Analyst RatingsNewsPrice Target
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and lowers the price target from $48 to $46.
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and lowers the price target from $48 to $46.